Zymeworks moves to repeat the Ziihera trick
The company adds royalty aggregation to its R&D business.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
Ziihera bags a gastric win
But Enhertu is coming.
For $3bn J&J holds on to Halda
The private biotech adds another asset to J&J’s prostate cancer pipeline.
Nuvalent presses ahead in ALK
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
Amgen goes pivotal with subcutaneous Blincyto
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
